Literature DB >> 17111347

Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides.

Sandra S Diebold1, Catherine Massacrier, Shizuo Akira, Carine Paturel, Yannis Morel, Caetano Reis e Sousa.   

Abstract

Toll-like receptor 7 (TLR7) mediates innate responses by responding to viral RNA in endocytic compartments. However, the molecular pattern recognised by TLR7 and whether it differs between RNA of viral and self origin remains unclear. Here, we identify nucleic acids that act as TLR7 agonists for mouse and human cells. We show that uridine and ribose, the two defining features of RNA, are both necessary and sufficient for TLR7 stimulation, and that short single-stranded RNA (ssRNA) act as TLR7 agonists in a sequence-independent manner as long as they contain several uridines in close proximity. Consistent with the notion that TLR7 lacks specificity for sequence motifs, we show that it is triggered equally efficiently by viral or self RNA delivered to endosomes. Our results support the notion that TLR7 recognises uracil repeats in RNA and that it discriminates between viral and self ligands on the basis of endosomal accessibility rather than sequence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111347     DOI: 10.1002/eji.200636617

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  92 in total

1.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Authors:  Kazuo Suzuki; Takaomi Ishida; Makoto Yamagishi; Chantelle Ahlenstiel; Sanjay Swaminathan; Katharine Marks; Daniel Murray; Erin M McCartney; Michael R Beard; Marina Alexander; Damian F J Purcell; David A Cooper; Toshiki Watanabe; Anthony D Kelleher
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

2.  mRNA: Fulfilling the Promise of Gene Therapy.

Authors:  Drew Weissman; Katalin Karikó
Journal:  Mol Ther       Date:  2015-09       Impact factor: 11.454

Review 3.  Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity.

Authors:  A G Bowie
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 4.  Toll-like receptors regulation of viral infection and disease.

Authors:  Joseph M Thompson; Akiko Iwasaki
Journal:  Adv Drug Deliv Rev       Date:  2007-12-28       Impact factor: 15.470

5.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Authors:  Sibylle Tluk; Marion Jurk; Alexandra Forsbach; Risini Weeratna; Ulrike Samulowitz; Arthur M Krieg; Stefan Bauer; Jörg Vollmer
Journal:  Int Immunol       Date:  2009-03-30       Impact factor: 4.823

6.  Gene silencing below the immune radar.

Authors:  Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-03       Impact factor: 14.808

Review 7.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

8.  Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands.

Authors:  Nathaniel M Green; Krishna-Sulayman Moody; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 9.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.

Authors:  Aimee L Jackson; Peter S Linsley
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

10.  Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.

Authors:  Sylvia Adams; David W O'Neill; Daisuke Nonaka; Elizabeth Hardin; Luis Chiriboga; Kimberly Siu; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Erika Ritter; Rose Marie Holman; Richard L Shapiro; Russell S Berman; Natalie Berner; Yongzhao Shao; Olivier Manches; Linda Pan; Ralph R Venhaus; Eric W Hoffman; Achim Jungbluth; Sacha Gnjatic; Lloyd Old; Anna C Pavlick; Nina Bhardwaj
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.